|10/30/2018||Composition of the Nomination Committee of Orion Corporation|
|10/24/2018||Orion Group Interim Report January-September 2018|
|10/24/2018||Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met|
|9/19/2018||Changes in responsibility areas of the Orion Group Executive Management Board|
|11/1/2018||Orion Research Foundation grants million euros for research in 2019|
|10/24/2018||Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland|
|10/10/2018||Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018|
|9/17/2018||Creation of novel medicines and better patient care for the future in an ecosystem|
As the cost pressures on pharmaceutical companies increase, Orion needs to constantly improve its efficiency to stay competitive. In 2016, the company began a group-wide Lean program, where the entire staff is involved in a culture of continuous improvement. Orion’s shift toward Lean culture received the Lean Prize 2016 from Lean Association of Finland.
11 January 2017 | On 1st November 2016 the Innovative Medicines Initiative (IMI) together with an association of industrial partners came together to support PHAGO, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD).